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ABSTRACT 
Background: Endoscopic management of upper urinary tract transitional cell carcinoma has 
assumed an important role in diagnosis and treatment. The introduction of small diameter rigid 
and flexible ureteroscopes has permitted access to the upper tract. Biopsy techniques have 
been developed for accurate diagnosis and the addition of lasers has given the urologists an 
excellent tool for treatment.  
Methods: Medical literature available relative to the endoscopic laser treatment of upper tract 
neoplasms has been reviewed.  
Results: Ureteroscopic treatment has been characterized by good success with high 
recurrence rates, both in the upper tract and the bladder. Bladder recurrence rates are similar to 
those seen after surgical treatment of upper tract tumors. Surveillance has been ureteroscopic 
since the other diagnostic options are inadequate. The holmium and neodymium:YAG lasers 
are the devices most commonly used now for the endoscopic treatment of upper tract tumors. 
Conclusion: Ureteroscopic treatment of upper tract neoplasms usually with ablation and 
resection using the neodymium and holmium:YAG lasers is a current acceptable procedure. 
This should be reconsidered as one of the options in tumor treatment.   
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Transitional cell carcinoma of the upper urinary tract is an uncommon lesion but is a 
potentially lethal tumor requiring treatment. Treatment has traditionally been surgical, either with 
nephroureterectomy or for low grade distal ureteral tumors, distal ureterectomy, including a wide 
bladder cuff around the orifice. 1,2 
The development of small, rigid and flexible ureteroscopes in the early 1980’s became 
possible with the introduction of fiberoptic illumination and imaging. These instruments have 
permitted routine access to the entire upper collecting system3 and have revolutionized the 
treatment of calculi and neoplasms. The Holmium:YAG and the Neodymium:YAG lasers are 
both effective for neoplasms and can be delivered through small flexible fibers.4,5  
 
INSTRUMENTS 
Endoscopes 
Small rigid endoscopes are available in single and dual channel designs ranging from 
approximately 5 to 9+French tip diameter (most commonly ~7F with a 3.6F channel).6  Dual 
channel designs allow for simultaneous irrigation and placement of a working device. These 
endoscopes can be passed easily under direct vision into the distal ureter to inspect that area 
without any prior instrumentation (i.e. termed the “no touch” inspection technique), but cannot 
adequately inspect the renal pelvis or intrarenal collecting system.  
Actively deflectable, flexible ureteroscopes were developed to access the intrarenal 
collecting system and proximal ureter atraumatically. They are available in single channel 
designs from 7.4 to 9+F while a larger endoscope is available with dual channels. The smaller 
diameter endoscopes can also be placed under direct vision frequently without trauma of 
guidewire introduction, thus, employing a “no touch” technique. To inspect the lower pole calyx 
in most kidneys, the ureteroscope must deflect 170o but to compensate for loss of deflection 
with working instruments in the channel, the active tip deflection has been increased to nearly 
300o in most ureteroscopes. 
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 Recently, flexible ureteroscopes have been constructed with digital imaging chips at the 
tip. These produce an excellent endoscopic image with better resolution but suffer from a larger 
overall diameter of nearly 10F as well as limited deflectability. Although it has been suggested 
that these instruments will have greater durability, this remains to be demonstrated.  
 
Lasers 
The Holmium and Nd:YAG lasers are effective devices for treating neoplasms 
throughout the urinary tract. The characteristics of these lasers are listed in Table 1. The 
Nd:YAG at a wavelength of 1064 nm destroys tissue with coagulation. It has a depth of 
penetration up to several millimeters (5-10)  in tissue or water and therefore, direct contact of 
the fiber with the neoplasm is not necessary. It is effective in treating tumors up to centimeters 
in diameter. However, it is difficult to judge the depth of penetration during treatment. It can be 
combined with techniques to remove the coagulated tissue.  
The Holmium YAG laser is a pulsed device with a wavelength of 2100 nm. It can cause 
coagulation at lower energies and higher pulse durations and can ablate the tissue coagulated 
either with the holmium or the Nd:YAG laser. The Holmium energy penetrates tissue only <0.4 
mm and therefore its effect is relatively superficial and is endoscopically visible.  
Fibers of various sizes can be used with either laser. Each fiber consists of a central 
core and a cladding with resultant diameter and deflection characteristics. The most commonly 
used fibers are 200 or 365µ diameter. The smaller fiber is more flexible but is a less efficient 
ablator of tissue since it has an exponentially smaller spot size, and, with the holmium:YAG,  a 
much smaller vaporization bubble.   
Other lasers, like the diode and the thulium, can be delivered with flexible fibers but have 
not yet been used and/or reported in significant clinical series of patients with upper urinary tract 
urothelial tumors. 
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Biopsy Devices 
Tissue samples can be taken with several different devices, indwelling baskets, forceps, 
graspers, snares and brushes. The most effective basket is a stainless steel flat wire design 
which can be closed to trap the tissue in the angle between the wires.   
Several designs of 1 mm diameter cup forceps are available and are useful in sampling 
flat or solid, nonpapillary lesions with a small sample fully contained within the cup, the device 
can be withdrawn through the working channel and replaced to obtain multiple tissue fragments. 
The stiffness of the shaft of the forceps often prohibits endoscope deflection of more than 90 to 
100o depending on the endoscope used.  The other instruments are relatively ineffective in 
obtaining tissue and are rarely used. 
 
TECHNIQUES 
Suspected upper tract neoplasms are often evaluated with contrast CT scan, (CT 
urogram, CTU), intravenous pyelogram or retrograde ureteropyelogram. The suspected lesion is 
then diagnosed endoscopically. The appearance is similar to that of urothelial tumors within the 
bladder and may be papillary, sessile or flat. In one series, visual inspection alone was only 
70% accurate in determining the malignancy or grade of a neoplasm in the upper tract.7 
It is also important to obtain a sample of tissue for pathologic diagnosis, since the grade 
of the tumor is important in the decision process for treatment. Papillary lesions can be sampled 
with a stainless steel flat wire basket which is applied around the tumor and closed snugly but 
not completely. It is then used to avulse a piece of tissue. The entire unit of tumor, basket and 
endoscope are removed to preserve the largest piece of tissue available. Samples should not 
be withdrawn with a basket through the channel since most of the sample would be sheared off 
and lost.  
Alternatively, for smaller, sessile or flat lesions, a cup forceps is used. Multiple samples 
should be taken. If the entire sample is contained within the cup, it can be withdrawn through 
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the channel of the ureteroscope. If there is a larger piece extending  beyond the extent of the 
cup, then again the entire unit of tumor, forceps and endoscope should be removed to maintain 
the largest sample.  
The tissue sample is delivered directly into a collection tube with a small aliquot of 
saline. If there will be a delay in delivering the sample to the cytopathology laboratory, the 
appropriate amount of cytologic preservative is added.  All tissue samples are processed as 
cytology specimens to avoid loss of tissue in preparation.8  A cell block can be made for 
macroscopically visibly evident samples.   
After adequate sampling, the tumor can be treated. Very small (1 to 2 mm) lesions can 
be treated effectively and completely with the holmium laser using few pulses. We commonly 
prefer to use the holmium laser for all ureteral lesions because of the lower risk of ureteral 
stricture with this controlled energy source. Localized tissue reaction with subsequent stricture 
may result from treatment of larger lesions or those encompassing more than one-half 
circumference of the ureter or from the use of the neodymium:YAG laser which causes a deeper 
tissue effect. (Table 1)9 
Specific capabilities of the Ho or Nd:YAG lasers can be utilized to maximize coagulation 
or ablation of neoplasms throughout the bladder or upper tract. Selection of the laser depends 
on the size and location of the lesion. The holmium laser alone can coagulate tumors with the 
maximum coagulative effect given by defocussing the laser beam on the tissue. Close 
approximation of the tip of the fiber or contact with the tissue gives a more ablative effect and 
removes tissue. Generally, there is less bleeding with the coagulative technique.  
Specific holmium lasers have variable pulse durations which can be employed to obtain 
unique tissue effects.  The longer pulse provides the same energy per pulse giving less intensity 
and improved coagulation. It retains some ablative properties while the shorter pulse duration 
maximizes the ablative effect. 
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The Neodymium YAG laser is a continuous wave device producing a wavelength which 
penetrates more deeply into tissue. Its major effect is coagulative and is very useful for deeper 
coagulation of larger tumors. It produces no ablation and the resultant coagulated tissue can be 
removed mechanically or with a Ho laser. Care must be taken with the Nd:YAG laser to avoid 
treating the ureteral wall circumferentially since it penetrates deeply and can result in a stricture.  
Within the renal pelvis, the energy choice depends mainly upon the size of the lesion. 
Larger vascular tumors (>1 cm) can be coagulated initially with the neodymium:YAG and then 
ablated and cleared with the holmium when a combination laser is available. These lesions can 
also be treated with the holmium laser alone. Lower holmium energy tends to maximize the 
coagulative effect and minimize the risk of bleeding (e.g. 0.5 to 0.6 joules and 5 hertz). When a 
laser with a variable pulse duration is available, the longer duration is used to maximize the 
coagulative effect and minimize bleeding.  
Adequate removal of neoplastic tissue without penetration of the pelvis or the ureter is 
highly technique dependent. The fiber of the holmium laser is applied only where the 
coagulative or ablative effect is desired. When the tumor partially obscures the ureter or renal 
pelvis, the laser is moved in an arc along the normal contour at the base of the neoplasm. It is 
helpful to initiate resection at the more proximal portion of the tissue and then work distally. In 
this way, it is possible to avoid advancing the fiber into the mucosa or wall of the ureter or renal 
pelvis.  
Some intrarenal locations are inherently difficult to treat with lasers. This occurs most 
commonly on the medial wall of the lower infundibulum. In these unusual situations, if it is 
impossible to reach with the 200 micron fiber, the flexible ureteroscope may deflect further with 
a 2F Bugbee electrode. This device also has the advantage of coagulation from the side of the 
tip. As opposed to laser fibers, it is not necessary to point the device directly at the tissue.  
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CLINICAL RESULTS 
Several papers have summarized reports of ureteroscopic treatment of upper tract 
transitional cell carcinoma (UUTTCC).10,11,12 Many of these papers have used lasers as one of 
the endoscopic ablative devices for treatment.  The earliest series, before the availability of the 
holmium laser, used electrocautery or electroresection while some were limited to rigid 
endoscopes. These reports are characterized by a high success rate for ablation of tumor with 
preservation of renal units. However, there is a high recurrence rate of the neoplasms. Kidneys 
have been preserved in approximately 70% of patients, while recurrences have ranged from 20-
88%. Therefore, endoscopic surveillance has an essential role in the treatment and follow up 
process after ureteroscopic treatment of UTTCC.  
New or recurrent bladder tumors are also common after the treatment of an upper 
urinary tract carcinoma (Table 2).  New or recurrent bladder tumors were seen after 
ureteroscopic treatment in 40.5% of patients in series up to 2001.13 Among more current series, 
there is also a wide range of bladder tumors appearing in 20-44% of patients. In comparison, 
bladder tumors have been reported to occur in from 15 to 45% of patients treated with open 
surgical nephroureterectomy and from 10 to 55% after laparoscopic nephroureterectomy. It is 
difficult to make direct comparisons, since the grade and stage of tumors, the intensity of 
endoscopic follow up and particularly the duration of follow up varies so widely. The rate of 
bladder tumors from these rough comparisons suggests that the rate of new or recurrent 
bladder tumors after endoscopic resection is not out of the range seen with 
nephroureterectomy.  
By far the most common complication after ureteroscopic treatment is ureteral stricture. 
This can occur either at the site of resection of a ureteral tumor or at other sites throughout the 
ureter. In a combined series a rate of 13.7% was reported in 2001.13 It is impossible to separate 
the strictures occurring in patients treated with lasers since all series include some treated with 
electrofulguration. The overall stricture rate in the series available is 12.7%, which is 
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considerably higher than the rate of <1% seen after the ureteroscopic treatment of ureteral 
stones.30 (Table 3) 
 
DISCUSSION 
 The standard treatment of upper tract neoplasms has been nephroureterectomy with 
excision of a bladder cuff. Studies in the 1970’s demonstrated the feasibility of distal 
ureterectomy to treat low grade distal ureteral neoplasms. Therapy was less successful for renal 
pelvic and proximal ureteral lesions suggesting a “downstream” effect.31,32 
 The next developmental step was to treat upper urinary tract tumors endoscopically. 
Based on the established endoscopic treatment of bladder tumors, the application of these 
techniques became limited only by the instrumentation available. This concept became a reality 
as appropriate ureteroscopes became available.33,34  The refinement of these endoscopes has 
made it possible to reach the entire intrarenal collecting system in most patients. 
 Similarly, instruments and techniques were developed to sample and treat upper tract 
tumors. Accurate diagnosis has improved by using cytologic techniques with cell blocks to 
identify larger samples.35,36  Ureteroscopic biopsies have been shown to have a high, but not 
perfect accuracy ranging from 80 to 90%.37,14   
Endoscopic access to the upper tract presents the opportunity for treatment. The first 
instruments for ablation and coagulation were 2 or 3F electrodes. In the series cited, patients 
dating from the early 1980’s were treated electrosurgically and often subsequently grouped with 
and then treated with lasers as they recurred during long term follow up.  Both the holmium:YAG 
and neodymium:YAG lasers can be delivered through small flexible fibers to the vast majority of 
surfaces within the upper collecting system.  
The Neodymium:YAG laser has been demonstrated to be an effective mechanism for 
the endoscopic treatment of bladder tumors. In a small series, it was shown to coagulate upper 
tract neoplasms successfully with an open surgical approach.38  The Neodymium:YAG laser can 
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effectively coagulate tissue, but it may be difficult to determine the depth of coagulation and the 
treated tissue remains in place and is not cleared. This is a minimal problem in the bladder but 
in the ureter or the renal pelvis, the coagulated tissue obscures deeper portions of the tumor 
which may be viable. This treated tissue must be removed mechanically or by ablation with the 
holmium laser. The holmium:YAG laser can also coagulate tissue primarily, although less  
efficiently. Lengthening the holmium pulse duration improves the coagulative effect.  Combining 
the Ho and Nd:YAG lasers gives maximal coagulative and ablative effects, delivering a more 
controlled coagulation and ablation of urothelial tumors than that delivered with a small cautery 
electrode.  
 The aim of the conservative management of upper tract neoplasms is to preserve renal 
function. This may be considered imperative or strongly indicated in patients with a solitary 
kidney, solitary functioning kidney or limited renal function. The alternative of 
nephroureterectomy with subsequent dialysis, and even possible later transplantation, must be 
considered and offered to the patient. There is a high morbidity and also mortality associated 
with dialysis.  In a recent series of 128 hemodialysis patients with a mean age of 61 years, the 3 
year survival was only 55%.39  Data from end stage renal disease database shows a decrease 
in survival in older patients.40  Five year survival over the last cited year (2001) was 30.7% for 
patients ages 65-69, 20.2% for those 70-79 and dropped to 9.6% at ≥ 80 years. 
Recently, the risks of chronic renal failure associated with a solitary kidney have become 
evident.41  There is interest in for maintaining renal function and avoiding development of an 
anephric state. Much of this emphasis has been directed toward the development of 
laparoscopic partial nephrectomy. However, the same arguments can be applied to UUTTCC.  
 The treatment of upper tract neoplasm with ureteroscopic techniques is quite successful. 
Low grade tumors carry a low mortality with treatment by many means including ureteroscopy. 
High grade tumors have a more pessimistic prognosis in general, with lower survival rates after 
either nephroureterectomy or endoscopic treatment.  When high grade tumors are treated 
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ureteroscopically, often palliatively, most patients maintain renal function with acceptable local 
control. Overall, ureteroscopic treatment of upper tract tumors has an excellent disease specific 
survival and results in approximately 70% renal maintenance.42  
 There are also both recognized and potential risks from ureteroscopic treatment. There 
remains a very high recurrence rate in most series ranging from 20 to 85%. Generally, the more 
recent reports have higher recurrence rates. This may be related to the longer follow up in these 
series. Alternatively, it may be related to the treatment of larger and more proximal neoplasms 
which in a surgical series have been shown to be more likely to have distal recurrences. The 
progression of grade is also possible approximating 10% in a large series. Therefore, it is 
essential that treated patients have endoscopic follow up since the noninvasive modalities of 
urinalysis, urinary cytology or FISH studies are inadequate to define recurrence.43,44,45 
 Cost has become an important consideration in guiding treatment.  Repetitive treatment 
or repetitive endoscopic surveillance can be an ongoing expense for health systems. In the US, 
the high cost associated with transplantation, or the even greater costs of hemodialysis makes 
endoscopic treatment and surveillance an attractive alternative. In comparison, in the medicare 
payment system, hemodialysis was the most expensive while successful ureteroscopic 
treatment with surveillance was the least expensive. There can be expected to be variations in 
different national health systems.42  
There remain many unknown factors involved in the endoscopic therapy of upper tract 
TCC.  For example, it is impossible to determine the exact stage of the neoplasm. Several 
series have shown that the stage is related to the grade.46  The latter can be obtained from 
ureteroscopic biopsy with a reasonably high accuracy when compared with the grade seen on 
surgical specimens.  Other staging studies, such as CT scanning, can be useful but do not have 
sufficient resolution for lower stages. Currently, tumor grade remains the best prognosticator. 
 The sources of urothelial tumor recurrences are unknown. It may be related to the field 
change in patients with urothelial carcinoma. This is supported from the known 5 to 10% 
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bilaterality of upper tract neoplasms. Similarly, the high risk of new or recurrent tumors at similar 
rates after ureteroscopic treatment or open or laparoscopic nephroureterectomy suggests a field 
change rather than seeding.  However, cytologically intact cells can be seen in the irrigant after 
endoscopic laser treatment.47 Their role in recurrence is unknown. Another unknown is the 
process of treatment itself.  It is impossible to determine the adequacy of coagulation and 
ablation visually.  For example, the depth of penetration from the neodymium:YAG laser is 
never certain except by visual inspection, which is inadequate. Similarly, the extent or presence 
of invasion of the neoplasm is impossible to determine.  
Adjuvant therapy has been considered as a means to reduce recurrence.  Agents such 
as topical Mitomycin, used after endoscopic resection, may have a role in decreasing 
recurrence in the upper tract as it has in the bladder.48 It has been employed in two short 
series.49,50  It has been demonstrated to be tolerated but there are insufficient data to determine 
its efficacy.  
 
CONCLUSION 
 Currently, ureteroscopic laser resection of upper tract neoplasms is an acceptable option 
for treatment.  It is an excellent first choice for patients with a solitary kidney, compromised 
contralateral kidney or impaired renal function. It has been used with very good success 
electively in patients with small low grade tumors and a normal contralateral kidney in an effort 
to preserve renal function. All patients must be followed endoscopically and must be willing to 
agree to endoscopic surveillance because of the high risk of recurrence in the upper tract and 
bladder. The holmium and neodymium:YAG lasers are presently the most commonly used 
devices. The laser combining Nd and Holmium:YAG is convenient and effective but the 
holmium:YAG lasers can be used alone, preferentially with the variable pulse duration.  
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Table 1 
 
Use of Ho and ND:YAG Laser for  
Ureteroscopic Treatment of UTTCC* 
 
       Site 
Laser  Kidney Ureter  Bladder 
Ho  8  40  5 
Nd  2  --  6 
Ho & Nd 34  2  22 
 
     Total 77 procedures (some with > 1 site) 
     Over 1 year (11/08 – 11/09) 
 
       *D Bagley unpublished 
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Table 2 
 
    
 
New or Recurrent Bladder Tumors: 
 
After Ureteroscopic Treatment of  UUTTCC 
 
   Reference           Bladder Tumor % 
 
   Sowter et al16*      12/35   34.3 
 
   Thompson et al15   37/83   44.6 
  
   Daneshmand et al14   6/30   20.0 
 
   Chen & Bagley13o     41/101   40.5 
    
   Combined     96/249   38.5 
*No history BT   
    
oreviewed series to 2001  
 
 
After Laparoscopic or Open Nephroureterectomy for UUTTCC 
       %   %  
       Laparoscopic Open 
Reference 
Rassweiler17    24.0   24.7 
Wolf18     55   -- 
Okegawa19    20   17 
Tsujihata20    28   33 
Raman 21    29   35 
Chung22    44   36 
Manabe23    32.8   38.0 
Muntener24    41   -- 
Roupret25    10   15 
Taweemonkongsap26   29   45 
Waldert27    26   27 
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               Table 3 
 
     Strictures after Ureteroscopic 
     Treatment of UUTTCC 
 
   Reference  Patient Stricture % 
   Suh et al28  16      2  12.5 
   Daneshmand et al14 30      5  16.7 
   Johnson et al29 35      3  8.5 
   Sowter et al16  40      4  10.0 
   Chen et al13*  139      19  13.7 
     Overall  260      33  12.7 
    
*combined series to 2001  
 
 
